ClinicalTrials.gg
CompletedNCT03036124DAPA-HFUpdated Sep 1, 2020Results posted

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

A Phase 3 interventional study of Dapagliflozin and Placebo in Chronic Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by AstraZeneca. Completed at 419 sites in 20 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2020-09-01.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,744
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
4th of 59
4,744 · median 100
Started
2017
with 1 other
Phase 3
16 of 59
5 open now
Registered
4th of 59
by date
Lead sponsor
7 of 59
AstraZeneca

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 4th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction

Read the detailed description

This is an international, multicentre, parallel group, event-driven, randomized, double-blind, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction (HFrEF), evaluating the effect of dapagliflozin versus placebo, given once daily in addition to background regional standard of care therapy, for the prevention of cardiovascular (CV) death or reduction of heart failure (HF) events.

03

Conditions studied

  • Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Browse trials for

Keywords

  • HFrEF
  • Heart Failure (HF)
  • Cardiovascular Events (CV)
  • Phase III outcome trial
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study specific procedures
  • Male or female, aged ≥18 years
  • Established documented diagnosis of symptomatic HFrEF ( functional class II-IV), which has been present for at least 2 months
  • ≤40%
  • Elevated NT-proBNP levels
  • Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines
  • ≥30 mL/min/1.73 m\^2 (CKD-EPI formula) at enrolment (visit 1)

Exclusion criteria

Exclusion Criteria:

  • Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
  • Type 1 diabetes mellitus
  • Symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2
  • Current acute decompensated HF or hospitalization due to decompensated HF \<4 weeks prior to enrolment
  • MI, unstable angina, stroke or within 12 weeks prior to enrolment
  • Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
  • Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device
  • Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
  • HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
  • Symptomatic bradycardia or second or third degree heart block without a pacemaker
  • Severe ( \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,744 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Patients will be randomized 1:1 to either dapagliflozin or placebo.

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Placebo matching dapagliflozin.

    Drug: Placebo

Interventions

  • 10 mg or 5 mg tablets given once daily, per oral use.

    Also known as: Forxiga TM, Farxiga TM

  • DrugPlacebo

    Placebo matching dapagliflozin 10 mg or 5 mg.

06

What researchers measure

Primary outcomes

  1. Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.

    Primary efficacy

    Time frame: Up to 27.8 months.

Secondary outcomes

  1. Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.

    Secondary

    Time frame: Up to 27.8 months.

  2. Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.

    Secondary

    Time frame: Up to 27.8 months.

  3. Change From Baseline in the KCCQ Total Symptom Score

    KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: Baseline and 8 months or death before 8 months

  4. Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.

    Secondary

    Time frame: Up to 27.8 months.

  5. Subjects Included in the Endpoint of All-cause Mortality.

    Secondary

    Time frame: Up to 27.8 months.

07

Results

Posted Sep 1, 2020

Participant flow

Participant flow — Overall Study
MilestoneDapa 10mgPlacebo
Started23732371
Completed23682365
Not completed56
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject54

Outcome measures

PrimarySubjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.

Primary efficacy

Time frame:
Up to 27.8 months.
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.386502
Statistical analysis
  • Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.74 · 95% CI 0.65 to 0.85Stratified by Type 2 Diabetes status at randomization and including the history of hospitalizations due to Heart failure as a factor.
SecondarySubjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.

Secondary

Time frame:
Up to 27.8 months.
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.382495
Statistical analysis
  • Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.75 · 95% CI 0.65 to 0.85Stratified by Type 2 Diabetes status at randomization and including the history of hospitalizations due to Heart failure as a factor.
SecondaryEvents Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.

Secondary

Time frame:
Up to 27.8 months.
Reported as:
Number · events
Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.
eventsDapa 10 mgPlacebo
Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.567742
Statistical analysis
  • Placebo · LWYY proportional rates model · p = 0.0002 · Rate ratio (rr): 0.75 · 95% CI 0.65 to 0.88Stratified by Type 2 Diabetes status at randomization and including the history of hospitalizations due to Heart failure as a factor.
SecondaryChange From Baseline in the KCCQ Total Symptom Score

KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

Time frame:
Baseline and 8 months or death before 8 months
Reported as:
Mean · Scores on a scale
Change From Baseline in the KCCQ Total Symptom Score
Scores on a scaleDapa 10 mgPlacebo
Change From Baseline in the KCCQ Total Symptom Score6.1 ± 18.63.3 ± 19.2
Statistical analysis
  • Placebo · Win Ratio · p = <0.0001 (The p-value is obtained from a rank ANCOVA adjusted for baseline KCCQ score and stratified by T2DM status at randomization.) · Win ratio (wr): 1.18 · 95% CI 1.11 to 1.26The composite of change from baseline in total symptom score at 8 months, or death before 8 months.
SecondarySubjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.

Secondary

Time frame:
Up to 27.8 months.
Reported as:
Count of participants · Participants
Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.2839
Statistical analysis
  • Placebo · Regression, Cox · p = 0.1681 · Hazard ratio (hr): 0.71 · 95% CI 0.44 to 1.16Stratified by Type 2 Diabetes status at randomization and including baseline eGFR as a covariate.
SecondarySubjects Included in the Endpoint of All-cause Mortality.

Secondary

Time frame:
Up to 27.8 months.
Reported as:
Count of participants · Participants
Subjects Included in the Endpoint of All-cause Mortality.
ParticipantsDapa 10 mgPlacebo
Subjects Included in the Endpoint of All-cause Mortality.276329
Statistical analysis
  • Placebo · Regression, Cox · p = 0.0217 · Hazard ratio (hr): 0.83 · 95% CI 0.71 to 0.97Stratified by Type 2 Diabetes status at randomization.

Adverse events

Collected over Up to 28.3 months.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10mg286/2,368 (12.1%)895/2,368 (37.8%)299/2,368 (12.6%)
Placebo333/2,368 (14.1%)994/2,368 (42%)325/2,368 (13.7%)
Most frequent serious events
Showing 10 of 624
Most frequent serious events
EventDapa 10mgPlacebo
Cardiac failureCardiac disorders262/2368351/2368
PneumoniaInfections and infestations76/236882/2368
Cardiac failure congestiveCardiac disorders65/236870/2368
Cardiac failure acuteCardiac disorders42/236859/2368
Ventricular tachycardiaCardiac disorders34/236854/2368
DeathGeneral disorders48/236848/2368
Acute kidney injuryRenal and urinary disorders23/236846/2368
Atrial fibrillationCardiac disorders26/236839/2368
Acute myocardial infarctionCardiac disorders37/236838/2368
Cardiac failure chronicCardiac disorders27/236833/2368
Most frequent other events
Most frequent other events
EventDapa 10mgPlacebo
Cardiac failureCardiac disorders76/2368130/2368
HypotensionVascular disorders88/236873/2368
NasopharyngitisInfections and infestations63/236876/2368
Renal impairmentRenal and urinary disorders63/236856/2368
Atrial fibrillationCardiac disorders58/236852/2368

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dapa 10mgPlaceboTotal
Mean66.2 ± 11.066.5 ± 10.866.3 ± 10.9
Age, Customized
Age, Customized(Participants)Dapa 10mgPlaceboTotal
<=50208188396
>50216521834348
Age, Customized
Age, Customized(Participants)Dapa 10mgPlaceboTotal
<=6510329982030
>65134113732714
Age, Customized
Age, Customized(Participants)Dapa 10mgPlaceboTotal
<=6510329982030
66 - 758258861711
>755164871003
Sex: Female, Male
Sex: Female, Male(Participants)Dapa 10mgPlaceboTotal
Female5645451109
Male180918263635
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dapa 10mgPlaceboTotal
Hispanic or Latino381387768
Not Hispanic or Latino199219843976
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapa 10mgPlaceboTotal
White166216713333
Black or African American122104226
Asian5525641116
Native Hawaiian or other Pacific Islander022
American Indian or Alaska Native314
Other342963
Main etiology of HF
Main etiology of HF(Participants)Dapa 10mgPlaceboTotal
Ischaemic131613582674
Non-Ischaemic8578301687
Unknown200183383

4 further baseline measures are reported on the registry.

08

Study locations

419 sites
  • Research Site
    Fairhope, Alabama 36532, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Sheffield, Alabama 35660, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Stockton, California 95204, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Vista, California 92083, United States
  • Research Site
    Wilmington, Delaware 19803, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Lake Worth, Florida 33461, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    New Smyrna Beach, Florida 32169, United States
  • Research Site
    Pembroke Pines, Florida 33024, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Saint Augustine, Florida 32086, United States
  • Research Site
    Wellington, Florida 33449, United States
  • Research Site
    Atlanta, Georgia 30303, United States
  • Research Site
    Cumming, Georgia 30041, United States
  • Research Site
    Tucker, Georgia 30084, United States
  • Research Site
    Hazel Crest, Illinois 60429, United States
  • Research Site
    Jerseyville, Illinois 62052, United States
  • Research Site
    Peoria, Illinois 61614, United States
  • Research Site
    Louisville, Kentucky 40205, United States
  • Research Site
    Alexandria, Louisiana 71301, United States
  • Research Site
    Chalmette, Louisiana 70043, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Baltimore, Maryland 21120, United States
  • Research Site
    Baltimore, Maryland 21228, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Haverhill, Massachusetts 01830, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48532, United States
  • Research Site
    Lansing, Michigan 48910, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Minneapolis, Minnesota 55417, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Saint Louis, Missouri 63128, United States
  • Research Site
    Great Falls, Montana 59405, United States
  • Research Site
    Grand Island, Nebraska 68803, United States
  • Research Site
    Lincoln, Nebraska 68526, United States
  • Research Site
    Omaha, Nebraska 68105, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Bridgewater, New Jersey 08807, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Somerset, New Jersey 08873, United States
  • Research Site
    Bronx, New York 10459, United States
  • Research Site
    Buffalo, New York 14203, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    New York, New York 10001, United States
  • Research Site
    Orchard Park, New York 14127, United States
  • Research Site
    Poughkeepsie, New York 12601, United States
  • Research Site
    Rosedale, New York 11422, United States
  • Research Site
    Burlington, North Carolina 27215, United States
  • Research Site
    Cleveland, Ohio 44106-6010, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Altoona, Pennsylvania 16602, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Pittsburgh, Pennsylvania 15240, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Knoxville, Tennessee 37912, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Nashville, Tennessee 37212, United States
  • Research Site
    Tullahoma, Tennessee 37388, United States
  • Research Site
    Beaumont, Texas 77702, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Houston, Texas 77002, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    San Antonio, Texas 78234, United States
  • Research Site
    Tyler, Texas 75701, United States
  • Research Site
    Farmington, Utah 84025, United States
  • Research Site
    Falls Church, Virginia 22042, United States
  • Research Site
    Richmond, Virginia 23298, United States
  • Research Site
    Seattle, Washington 98101, United States
  • Research Site
    Seattle, Washington 98195, United States
  • Research Site
    Buenos Aires, C1180AAX, Argentina
  • Research Site
    Buenos Aires, C1425AGC, Argentina
  • Research Site
    Caba, 1428, Argentina
  • Research Site
    Caba, 1437, Argentina
  • Research Site
    Caba, C1119ACN, Argentina
  • Research Site
    Caba, C1120AAC, Argentina
  • Research Site
    Caba, C1425DQI, Argentina
  • Research Site
    Ciudad Autonoma Buenos Aires, 1093, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1221, Argentina
  • Research Site
    Cordoba, 5003, Argentina
  • Research Site
    Cordoba, X5006CBI, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Córdoba, X5004BAL, Argentina

Showing the first 100 of 419 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Docherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia. 2022 Mar 29;2(2):139-153. doi: 10.1016/j.jacasi.2022.02.004. eCollection 2022 Apr. PubMed 36339117 ↗
  • Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-1234. doi: 10.1001/jamacardio.2022.3736. PubMed 36189985 ↗
  • Adamson C, Cowan LM, de Boer RA, Diez M, Drozdz J, Dukat A, Inzucchi SE, Kober L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Lindholm D, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV, Jhund PS. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Eur J Heart Fail. 2022 Oct;24(10):1856-1868. doi: 10.1002/ejhf.2649. Epub 2022 Aug 22. PubMed 36054568 ↗
  • Docherty KF, Welsh P, Verma S, De Boer RA, O'Meara E, Bengtsson O, Kober L, Kosiborod MN, Hammarstedt A, Langkilde AM, Lindholm D, Little DJ, Sjostrand M, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Schou M, Solomon SD, Sattar N, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022 Sep 27;146(13):980-994. doi: 10.1161/CIRCULATIONAHA.122.060511. Epub 2022 Aug 16. PubMed 35971840 ↗
  • Butt JH, Dewan P, DeFilippis EM, Biering-Sorensen T, Docherty KF, Jhund PS, Kosiborod MN, Martinez FA, Bengtsson O, Johansen ND, Langkilde AM, Sjostrand M, Vaduganathan M, Solomon SD, Sabatine MS, Kober L, Fiuzat M, McMurray JJV. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009. Epub 2022 Jun 8. PubMed 35902157 ↗
  • Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019. Epub 2022 Apr 6. PubMed 35483792 ↗
  • Butt JH, Dewan P, Merkely B, Belohlavek J, Drozdz J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjostrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Kober L, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022 Jun;175(6):820-830. doi: 10.7326/M21-4776. Epub 2022 Apr 26. PubMed 35467935 ↗
  • Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjostrand M, Vaduganathan M, Jhund PS, McMurray JJV. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation. 2022 Aug 9;146(6):438-449. doi: 10.1161/CIRCULATIONAHA.121.058910. Epub 2022 Apr 20. PubMed 35442064 ↗
  • Docherty KF, Simpson J, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Sjostrand M, Lindholm D, Langkilde AM, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC Heart Fail. 2022 Feb;10(2):104-118. doi: 10.1016/j.jchf.2021.09.002. Epub 2022 Jan 12. PubMed 35115084 ↗
  • Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'Meara E, Verma S, Inzucchi SE, Kober L, Kosiborod MN, Lindholm D, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2022 Jan;10(1):52-64. doi: 10.1016/j.jchf.2021.08.006. Epub 2021 Nov 10. PubMed 34969498 ↗
  • Ryden L, Ferrannini G. Is the impact of add on heart failure therapy influenced by background therapy? Lancet Diabetes Endocrinol. 2022 Jan;10(1):3-5. doi: 10.1016/S2213-8587(21)00311-9. Epub 2021 Nov 30. No abstract available. PubMed 34861151 ↗
  • Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O'Meara E, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Jhund PS, McMurray JJV, Kober L. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circ Heart Fail. 2021 Dec;14(12):e008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837. Epub 2021 Nov 22. PubMed 34802253 ↗
  • Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O'Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjostrand M, McMurray JJV, Sabatine MS, Morrow DA. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2022 Jan 18;145(3):158-169. doi: 10.1161/CIRCULATIONAHA.121.057852. Epub 2021 Nov 8. PubMed 34743554 ↗
  • Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021 Sep 21;42(36):3727-3738. doi: 10.1093/eurheartj/ehab560. PubMed 34448003 ↗
  • Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632. PubMed 34319398 ↗
  • Adamson C, Jhund PS, Docherty KF, Belohlavek J, Chiang CE, Diez M, Drozdz J, Dukat A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjostrand M, McMurray JJV. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021 Oct;23(10):1662-1672. doi: 10.1002/ejhf.2308. Epub 2021 Jul 29. PubMed 34272791 ↗
  • Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Bohm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjostrand M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 May 18;143(20):1962-1972. doi: 10.1161/CIRCULATIONAHA.121.053659. Epub 2021 Apr 9. PubMed 33832352 ↗
  • Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O'Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjostrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Kober L. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiol. 2021 Jun 1;6(6):678-689. doi: 10.1001/jamacardio.2021.0379. PubMed 33787831 ↗
  • Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjostrand M, Solomon SD, McMurray JJV, Sabatine MS. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021 May 1;6(5):499-507. doi: 10.1001/jamacardio.2020.7585. PubMed 33595593 ↗
  • Shen L, Kristensen SL, Bengtsson O, Bohm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O'Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjostrand M, Solomon SD, Jhund PS, McMurray JJV. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail. 2021 Apr;9(4):254-264. doi: 10.1016/j.jchf.2020.11.009. Epub 2021 Feb 3. PubMed 33549554 ↗
  • Dewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjostrand M, Solomon SD, Verma S, Jhund PS, McMurray JJV. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail. 2021 Apr;23(4):632-643. doi: 10.1002/ejhf.2083. Epub 2021 Jan 18. PubMed 33368858 ↗
  • Inzucchi SE, Docherty KF, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Belohlavek J, Bohm M, Chiang CE, de Boer RA, Diez M, Dukat A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjostrand M, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18. PubMed 33355302 ↗
  • Yeoh SE, Dewan P, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Sjostrand M, Langkilde AM, McMurray JJV; DAPA-HF Investigators and Committees. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Circ Heart Fail. 2020 Dec;13(12):e007879. doi: 10.1161/CIRCHEARTFAILURE.120.007879. Epub 2020 Nov 9. PubMed 33164553 ↗
  • Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjostrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402. Epub 2020 Sep 2. PubMed 33082245 ↗
  • Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjostrand M, McMurray JJV. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12. PubMed 33040613 ↗
  • Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau JC, O'Meara E, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. 2020 Oct 27;142(17):1623-1632. doi: 10.1161/CIRCULATIONAHA.120.047480. Epub 2020 Sep 4. PubMed 32883108 ↗
  • Serenelli M, Bohm M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjostrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020 Sep 21;41(36):3402-3418. doi: 10.1093/eurheartj/ehaa496. PubMed 32820334 ↗
  • Jackson AM, Dewan P, Anand IS, Belohlavek J, Bengtsson O, de Boer RA, Bohm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukat A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O'Meara E, Sabatine MS, Sjostrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020 Sep 15;142(11):1040-1054. doi: 10.1161/CIRCULATIONAHA.120.047077. Epub 2020 Jul 16. Erratum In: Circulation. 2020 Nov 17;142(20):e369. doi: 10.1161/CIR.0000000000000939. PubMed 32673497 ↗
  • Solomon SD, Jhund PS, Claggett BL, Dewan P, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJV. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail. 2020 Oct;8(10):811-818. doi: 10.1016/j.jchf.2020.04.008. Epub 2020 Jul 8. PubMed 32653447 ↗
  • Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjostrand M, Langkilde AM, Anand IS, Belohlavek J, Chopra VK, Dukat A, Kitakaze M, Merkely B, O'Meara E, Schou M, Vinh PN, McMurray JJV; DAPA-HF Investigators and Committees. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail. 2020 Jul;22(7):1247-1258. doi: 10.1002/ejhf.1867. Epub 2020 Jun 15. PubMed 32539224 ↗
  • Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906. Erratum In: JAMA. 2021 Apr 6;325(13):1335. doi: 10.1001/jama.2021.2802. PubMed 32219386 ↗
  • Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjostrand M, Langkilde AM, McMurray JJV. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17. PubMed 31736335 ↗
  • Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjostrand M, Langkilde AM, Jhund PS, McMurray JJV. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133. Epub 2019 Nov 17. PubMed 31736328 ↗
  • McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. PubMed 31535829 ↗
  • McMurray JJV, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD; DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019 Nov;21(11):1402-1411. doi: 10.1002/ejhf.1548. Epub 2019 Jul 15. PubMed 31309699 ↗
  • Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678. PubMed 31081589 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jul 2019, 29 months.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 29 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2017
First posted
Jan 30, 2017
StartActual
Feb 8, 2017
Primary completionActual
Jul 17, 2019
CompletionActual
Jul 17, 2019
Results first posted
Sep 1, 2020
Last update
Sep 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03036124
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
Feb 8, 2017
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019
Results posted
Sep 1, 2020
Last update
Sep 1, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion